Photo from archive.org
This review provides the rationale for dual pathway inhibition with the combination of low-dose rivaroxaban (2.5 mg twice daily) to attenuate thrombin generation and aspirin (100 mg once daily) to reduce platelet… Click to show full abstract
This review provides the rationale for dual pathway inhibition with the combination of low-dose rivaroxaban (2.5 mg twice daily) to attenuate thrombin generation and aspirin (100 mg once daily) to reduce platelet activation. Such therapy has been licensed for secondary prevention in patients with coronary or peripheral artery disease.
Keywords:
rivaroxaban plus;
pathway inhibition;
dual pathway
Journal Title: Thrombosis research
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Thrombosis research
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!